



ASGCT 27th Annual Meeting
May 7 – 11, 2022
Baltimore, MD

ASGCT Media Policies

Abstract Embargo

The full text of accepted abstracts will be made available to media registrants on April 8, 2024, two weeks before the content goes live to the public. Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. EST. Researchers and presenters are free to discuss the content of their abstracts throughout this embargo period, but any content related to abstracts may not be published until the abstracts are publicly released online.

Late-breaking abstracts will be released to the public on May 3, 2024, at 4:30pm ET. Media registrants will not have a premier release of these abstracts.

New data to be presented during sessions is embargoed until 6 a.m. ET on the presentation day. All data for poster presentations is held under embargo until 6 a.m. ET on the first day of the meeting.

After an abstract author has accepted their presentation role, the author and their organization are encouraged to publicize the title, author name, and presentation time across any channels they'd like, tagging ASGCT where applicable.

ASGCT will publish the titles and authors in the abstract collection upon the acceptance of notification.

Late Breaking Abstracts

Late breaking abstracts will be released to the public at 4:30 p.m. EST on May 3, 2024. Due to the emerging nature of late breaking abstracts and the expediency with which ASGCT needs to publish the information, **late breaking abstracts will not be available to the media prior to their public release.**

27th Annual Meeting Abstract Release Schedule

Submission Closes:

January 26, 2024

Author Notifications Sent:	March 25, 2024
Author Abstract Withdrawal Deadline:	April 1, 2024
27th Annual Meeting Abstracts Collection Released to Media:	April 8, 2024
27th Annual Meeting Abstracts Collection Released to Public:	April 22, 2024, 4:30 p.m. ET
Late-Breaking Abstracts Released to the Public:	May 3, 2024, 4:30 p.m. ET

Audio Recording, Video Recording, Photography, and Distribution of Presentations and Slides

Attendees and media registrants are required to abide by any recording, photography, or screen capture requests made by speakers at any ASGCT event.

Photography and recording for personal reference is allowed. However, attendees and media registrants may not share or republish any materials from ASGCT events, including but not limited to slides, unpublished data, or presentation materials, without explicit written permission from both the presenter and ASGCT.

Copyright Ownership

Authors assign copyright of the abstract to ASGCT upon submission, unless one of the authors is a U.S. Federal Employee. This means that encore or identical abstracts may not be republished or submitted to another meeting. ASGCT has no copyright over additional information shared in the oral or poster presentation which is not in the abstract.

Exhibiting, Public Relations, Advertising, and Marketing

Exhibitors and individuals representing industry, advertising, and marketing or public relations firms may not register as members of the media for the ASGCT Annual Meeting.

No exceptions will be made to the following policies:

- Materials may not indicate ASGCT endorsement or use the ASGCT/Annual Meeting logos unless provided by ASGCT.
- **Under no circumstances will contact information of registered press be made available. ASGCT can provide a list of registered media outlets upon request.** Individuals, companies, organizations, or institutions found in violation of these policies will have ASGCT Annual Meeting access revoked.

On-Site Meeting Protocols

All in-person attendees and media registrants must comply with ASGCT's requirements for [registration](#) and [conduct](#). If you have any other questions, please contact the communications team at media@asgct.org.

Publication Exceptions

In exceedingly rare circumstances, ASGCT may grant an exception to the embargo policy in order to comply with regulations from the Securities and Exchange Commission (SEC), other federal law, or international law.

Any exception request must be submitted to ASGCT in writing to CEO David Barrett (dbarrett@asgct.org), Senior Program Manager Alex Peterson (apeterson@asgct.org), Program Manager Kim Durham (kdurham@asgct.org), and Director of Communications Alex Wendland (awendland@asgct.org) at least 48 hours before the conclusion of the public embargo, and must include the following:

- Statement that an exception is required to abide by applicable securities laws
- Statement that the disclosed information is the absolute minimum necessary to comply with the applicable securities law
- The lead author and presenter (both if they are different) copied on any correspondence
- Signature of legal counsel
-

Whenever possible, ASGCT prefers any disclosure follow these guidelines:

- Do not include implications or translational interpretations of results
- Necessary data presented in qualitative terms rather than quantitative terms
- Include the submission to and upcoming presentation at the ASGCT Annual Meeting

For example, a press release stating “we’re hopeful that the research presented at the ASGCT Annual Meeting will bring gene therapy for [insert disease] closer to the clinic, and we’re excited to share additional updates during our presentation,” is a qualitative statement and preferred in the case of an exception. However, a statement such as “in the study submitted to ASGCT, 5 of 7 patients demonstrate no disease symptoms and we’ve applied for FDA fast track designation,” is a quantitative statement and should not be included in a release.